Creative Diagnostics Broadens Its Portfolio with New Pseudotyped GFP HPV
Creative Diagnostics introduces new Pseudotyped GFP HPV for for immunogenicity assessment in vaccine trials.
United States – April 29, 2021 /MarketersMedia/ —
As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently introduces new Pseudotyped GFP HPV for immunogenicity assessment in vaccine trials. This new series of HPV reporter virus particles can be used for measuring neutralizing anti-HPV antibodies in pseudovirion-based neutralization assays.
Human papillomaviruses (HPVs) are double-stranded non-enveloped DNA viruses that infect keratinocytes of stratified squamous epithelia. Immunogenicity assessments in vaccine trials have focused on measurements of antibody responses to the vaccine. Currently, the “gold standard” for measuring neutralizing anti-HPV antibodies is the pseudovirion-based neutralization assay (PBNA). Instead of using authentic viruses, pseudovirions with an encapsidated reporter can be used to avoid high risks and provide more direct measurements for antibodies.
Creative Diagnostics Pseudotyped GFP HPV production is based on the transfection of a 293 cell line, 293FT, engineered to express high levels of SV40 large T antigen. The cells are co-transfected with codon-modified papillomavirus capsid genes, L1 and L2, together with a pseudogenome plasmid containing the SV40 origin of replication. Pseudovirus (PsV) encapsidating a GFP reporter plasmid can be used to develop a high-throughput in vitro neutralization assay in a 96-well plate format.
In this release, various products are introduced to the research community, such as the Pseudotyped GFP HPV6 (Cat. No PSVG-HPV6), which is used to test the ability of serum and antibodies to neutralize the infectivity of HPV6. HPV6 Pseudoviruses are produced in 293FT cells using three separate plasmids, encoding the HPV L1 protein, the HPV L2 protein, and a reporter gene. HPV6 Pseudovirus display antigenically correct L1 and L2 protein pseudotyped on replication-incompetent virus particles. Pseudoviruses are capable of a single round of infection and carry a plasmid that expresses GFP optical reporter gene upon infection.
“HPVs compose a group of more than 100 genotypes that can cause cervical cancer and its precursor lesions. At present 12 types of HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) have been classified as carcinogenic types to humans and an additional 8 types are classified as possibly carcinogenic types to human. We can provide up to 15 different types of HPV pseudovirus, which include all 12 carcinogenic HPV types.” said Dr. Jessica Waldorf, chief scientific officer of R&D department of Creative Diagnostics.
“In addition to the Pseudotyped GFP HPV, Creative Diagnostics has established a global-leading virus-like particles (VLPs) manufacturing platform using an E. coli cell system. With years of exploration, our scientists have successfully obtained various highly purified HPV VLPs, which can be typically used for antibody discovery, diagnostic reagent development, and vaccine development. Our products have significantly contributed to HPV vaccine-related research. We’ll be glad to work with you to solve your challenges.” said Prof. Mike Knuth, M.D., the chief scientific officer of R&D department of Creative Diagnostics.
If you want to know more information about our Pseudotyped GFP HPV related products or other research materials, please visit Creative Diagnostics at https://www.creative-diagnostics.com/.
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. It aims to provide a trusted source for all researchers’ assay development and manufacturing needs.
Release ID: 89002751